AEMD

Aethlon Medical, Inc. (AEMD) - Q2 2024 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2024. Aethlon Medical, Inc. is a clinical-stage medical therapeutic company developing the Hemopurifier, an immunotherapeutic device designated as a "Breakthrough Device" by the FDA for treating advanced cancer and life-threatening viral infections. The company is currently conducting safety, feasibility, and dose-finding clinical trials in Australia and India.

Key Financial Metrics

Note: The company has no revenue. Operating expenses are primarily driven by professional fees, payroll, and general administrative costs.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by 8.6% ($273,227) for the three months ended September 30, 2024, compared to the same period in 2023. This was driven by a $562,266 reduction in professional fees (legal, contract labor, accounting) partially offset by a $181,473 increase in payroll expenses due to severance costs.
• Net Loss: Net loss decreased to $2.81 million for the quarter (from $3.03 million in Q2 2023) and $5.38 million for the six-month period (from $6.32 million in the prior year).
• Capital Structure: In May 2024, the company closed a public offering raising approximately $4.7 million in gross proceeds ($3.5 million net). Additionally, warrant exercises in June 2024 generated an additional $1.84 million in proceeds.
• Share Count: Outstanding common shares increased significantly from 2.63 million (March 31, 2024) to 13.96 million (September 30, 2024) due to the public offering and warrant exercises.

Outlook, Risks, and Management Commentary

• Clinical Progress: In November 2024 (subsequent event), the first two patients in the Australian oncology trial successfully completed screening and advanced to the run-in period. The India trial remains open pending patient admissions.
• Liquidity and Going Concern: Management states that existing cash as of September 30, 2024, is not sufficient to fund operations for at least twelve months. The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern without additional financing.
• Capital Needs: The company intends to fund future operations through debt/equity financing or strategic partnerships. Failure to secure capital could result in the inability to conduct clinical trials or commercialize products.
• Management Changes: Effective October 3, 2024, James B. Frakes was appointed permanent CEO (previously Interim CEO/CFO). Guy Cipriani was terminated as COO.
• Risks: Key risks include the need for additional financing, potential delisting from Nasdaq, regulatory approval uncertainties, and global economic instability affecting capital markets.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash depletion and the status of any new financing discussions, given the explicit "going concern" warning.
• Dilution Impact: Review the terms of the May 2024 offering and outstanding warrants (13.4 million warrants outstanding) to assess potential future dilution.
• Clinical Milestones: Monitor enrollment rates and safety data from the Australian and India trials, as these are critical for future funding and regulatory approval.
• Severance Costs: Confirm the total accrued separation expenses ($792,627 as of Sept 30) and any future cash outflows related to executive terminations.
• Internal Controls: Note the previously identified material weakness regarding segregation of duties in financial reporting and the status of remediation efforts.